PTC Therapeutics, Inc.
NASDAQPTC Therapeutics heads into its June 2 earnings report with fresh analyst momentum at its back — and a CEO who has just been selling. The standout this week is Jefferies, which upgraded PTCT to Buy just today, lifting its target from $76 to $85. That reverses the same firm's downgrade to Hold back in late March. The move adds to a wave of post-earnings analyst…
Snapshot as of 27 May 2026
PTC Therapeutics heads into its June 2 earnings report with fresh analyst momentum at its back — and a CEO who has just been selling. The standout this week is Jefferies, which upgraded PTCT to Buy just today, lifting…
PTC Therapeutics kicked off the week with a double-digit rally, driven by a Q1 earnings beat that cleared the bar by $0.42 EPS and pulled analysts back into the upgrade camp — a sharp reversal from the bearish drift…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PTCT — free to start on ORTEX.
Sign up for free →Open PTCT on ORTEX